Exchange: NASDAQ·Updated 04:10 PM EDT

OPRX News

News
all
press releases
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
Zacks
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?
The Trade Desk expands healthcare advertising with OptimizeRx, adding authenticated HCP inventory across 400+ EHR and e-prescribing systems.
Zacks
More News
OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network
The move gives life sciences advertisers a more streamlined way to bring specialized healthcare audiences into their broader digital media strategies.
Stocktwits
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx (OPRX) delivered earnings and revenue surprises of +45.46% and +0.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
PTC Inc. (PTC) Q3 Earnings and Revenues Miss Estimates
PTC Inc. (PTC) delivered earnings and revenue surprises of -1.25% and -2.90%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Commvault Systems (CVLT) Beats Q1 Earnings and Revenue Estimates
Commvault (CVLT) delivered earnings and revenue surprises of +20.34% and +0.99%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Pegasystems (PEGA) Lags Q2 Earnings and Revenue Estimates
Pegasystems (PEGA) delivered earnings and revenue surprises of -18.61% and -1.84%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
Zacks
OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?
OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.
Zacks
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
Zacks

Advertisement|Remove ads.